MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.630
-0.040
-2.40%
After Hours: 1.610 -0.02 -1.23% 18:41 06/24 EDT
OPEN
1.690
PREV CLOSE
1.670
HIGH
1.750
LOW
1.610
VOLUME
47.10K
TURNOVER
0
52 WEEK HIGH
12.00
52 WEEK LOW
1.550
MARKET CAP
25.20M
P/E (TTM)
-1.2593
1D
5D
1M
3M
1Y
5Y
Edesa Biotech Adds Mechanically Ventilated Patients To Late-Stage COVID-19 Study
Benzinga · 05/24 17:04
EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT
Benzinga · 05/24 14:41
Edesa Biotech Begins Enrollment of Second Cohort of Patients for Phase 3 Study of Acute Respiratory Distress Syndrome
MT Newswires · 05/24 08:29
Here's Why We're Not At All Concerned With Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 05/17 12:43
Edesa Biotech GAAP EPS of -$0.33
Edesa Biotech press release (NASDAQ:EDSA): Q2 GAAP EPS of -$0.33. At March 31, 2022, Edesa had working capital of $14.66 million. Cash and cash equivalents totaled $15.89 million.
Seekingalpha · 05/13 13:07
BRIEF-Edesa Biotech Inc - For The Quarter Ended March 31, 2022, Co Reported A Net Loss Of $4.57 Million, Or $0.33 Per Common Share
reuters.com · 05/13 13:06
-- Earnings Flash (EDSA) EDESA BIOTECH Reports Q2 Loss $-0.33
MT Newswires · 05/13 09:05
Edesa Biotech Reports Dermatitis Study Enrolling Faster Than Expected
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that patient recruitment for a Phase 2b clinical study evaluating the
Benzinga · 04/28 11:47
More
No Data
Learn about the latest financial forecast of EDSA. Analyze the recent business situations of Edesa Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EDSA stock price target is 16.33 with a high estimate of 18.00 and a low estimate of 15.00.
High18.00
Average16.33
Low15.00
Current 1.630
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 24
Institutional Holdings: 1.85M
% Owned: 11.99%
Shares Outstanding: 15.46M
TypeInstitutionsShares
Increased
7
68.77K
New
1
1.46M
Decreased
3
2.29K
Sold Out
4
30.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Sean Macdonald
President
Michael Brooks
Chief Executive Officer/Secretary/Director
Pardeep Nijhawan
Chief Financial Officer
Kathi Niffenegger
Director
Jennifer Chao
Director
Frank Oakes
Independent Director
Lorin Johnson
Independent Director
Paul Pay
Independent Director
Carlo Sistilli
No Data
No Data
About EDSA
Edesa Biotech, Inc. is a Canada-based biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. It is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. It is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.